Clinical trials: Refractory Shock
Cardiogenic Shock
Venous Oxygen Saturation During ECMO Support
Extracorporeal veno-arterial membrane oxygenation" (ECMO-VA), are used to manage refractory cardiogenic shocks by replacing the failed "heart-lung" block.
- Trial name
- ECMOxygen (NCT04934566)
- Testing
- ECMO flow
- Where
- France
- Volunteers
- 48 people
- Sponsor
- University Hospital, Lille
Cardiogenic Shock, Heart Failure
Veno-arterial Extracorporeal Membrane Oxygenation Prior to Left Ventricular Assist Device Implantation.
Cardiogenic shock is an uncommun pathology with a high mortatily rate around 45%. Veno arterial extracorporeal membrane oxygenation (VA-ECMO) is a temporary extracorporeal assist device which restore an adequate blood flow when a…
- Conditions
- Cardiogenic Shock, Heart Failure, Extracorporeal Membrane Oxygenation, Left Ventricular Assist Device
- Trial name
- LVAD-ECMO (NCT03583970)
- Testing
- Left Ventricular Assist Device Implantation
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Multiple Myeloma
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
This is a phase 2/3, open label trial for patients with relapsed-refractory multiple myeloma. Study agent is tanespimycin (KOS-953), at three different dose levels in combination with a fixed dose of bortezomib.
- Trial name
- TIME-2 (NCT00514371)
- Testing
- tanespimycin, Bortezomib
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- Bristol-Myers Squibb
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL
This phase II trial studies how well onalespib works in treating patients with anaplastic large cell lymphoma, mantle cell lymphoma, or diffuse large B-cell lymphoma that has not responded to previous treatment (refractory) or…
- Conditions
- Recurrent Anaplastic Large Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma
- Trial name
- NCT02572453
- Testing
- Onalespib
- Where
- 19 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Septic Shock, Refractory Shock
What Should be the Next Vasopressor for Severe Septic Shock? Methylene Blue or Terlipressin
The ICU mortality rate of patients with septic shock was still high upto 54.1%.In first 6 hours of resuscitation, the goals of resuscitation in sepsis shock after adequate fluid resuscitation is MAP ≥65 mmHg.
- Trial name
- NCT03038503
- Testing
- Methylene Blue, Terlipressin
- Where
- Thailand
- Volunteers
- 60 people
- Sponsor
- Ramathibodi Hospital
Shock, Cardiogenic, Extra-Corporeal-Life-Support ( ECLS)
Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Under VA ECMO
Refractory cardiogenic shock is characterized by a decreased in cardiac output with hypo-responsiveness to increasing doses of catecholamines resulting in a profound tissular ischemia.
- Conditions
- Shock, Cardiogenic, Extra-Corporeal-Life-Support ( ECLS), Autonomic Nervous System Diseases, Inflammation
- Trial name
- ADRECMO (NCT03327493)
- Testing
- Biological
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Central Hospital, Nancy, France
Acute Lymphoblastic Leukemia, Immune System Diseases
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
The body has different ways of fighting infection and disease. No single way is effective at fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells.
- Conditions
- Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
- Trial name
- NCT03016377
- Testing
- iC9-CAR19 cells, Rimiducid, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cardiogenic Shock, Extracorporeal Membrane Oxygenation
Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO
This multicenter randomized controlled trial compare two transfusion strategies of red blood cells transfusion in patients supported by veno-arterial extracorporeal membrane oxygenation for refractory cardiogenic shock.
- Conditions
- Cardiogenic Shock, Extracorporeal Membrane Oxygenation, Transfusion Related Complication, Anemia
- Trial name
- ICONE (NCT05699005)
- Testing
- Packed Red Blood Cells (PRBCs)
- Where
- 4 sites in France
- Volunteers
- 236 people
- Sponsor
- University Hospital, Lille
Sudden Cardiac Arrest, Out-of-hospital Cardiac Arrest (OHCA)
FEMART-1 Pilot Study
The FEMART-1 Pilot Study is focused on evaluating the feasibility, safety, and procedural timing of prehospital femoral arterial sheath placement in patients with non-traumatic out-of-hospital cardiac arrest (OHCA), both during…
- Conditions
- Sudden Cardiac Arrest, Out-of-hospital Cardiac Arrest (OHCA), Cardiogenic Shock Acute
- Trial name
- FEMART-1 (NCT07596446)
- Testing
- Prehospital Ultrasound-Guided Femoral Arterial Sheath Placement
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- Emergency Medical Service, Prague
Angina Pectoris
Treatment of Refractory Angina Pectoris by Shock Wave Therapy
The purpose of this study is to determine that extracorporeal shock wave therapy (ESWT) is safe and effective for the treatment of refractory angina pectoris.
- Trial name
- NCT00776568
- Testing
- Extra-corporeal shockwave, Anti-hypertensive drugs
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Universal Research Group
Advanced Breast Cancer, Treatment-Refractory Solid Tumors
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
The purpose of this study is to evaluate the safety and efficacy of TAS-116 with palbociclib in two groups of patients: Patients with advanced breast cancer that has become worse after taking palbociclib alone Patients with…
- Conditions
- Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency, SCLC
- Trial name
- NCT05655598
- Testing
- Palbociclib Oral Product, TAS-116
- Where
- United States
- Sponsor
- Brown University
Relapsed or Refractory Neuroblastoma
A Phase I Trial of Anti-GD2 T-cells (1RG-CART)
The purpose of this first in human study is to determine the safety and feasibility of 1RG-CART therapy in patients with relapsed or refractory neuroblastoma.
- Trial name
- NCT02761915
- Testing
- Leukapheresis, Cyclophosphamide, Fludarabine
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Cancer Research UK
Vasodilatory Shock
Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension
The goal of this clinical trial is to determine the safety and efficacy of Angiotensin-II in the treatment of pediatric patients in fluid refractory vasodilatory shock.
- Trial name
- NCT07212686
- Testing
- Angiotensin-II
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Septic Shock
The Effect of Early Use of Methylene Blue on Hemodynamics in Septic Shock
This study will include patients requiring high dose of norepinephrine (NA) to maintain blood pressure after fluid resuscitation.
- Trial name
- NCT04970602
- Testing
- Methylene Blue
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Xiangya Hospital of Central South University
Out-of-hospital Cardiac Arrest (OHCA)
Potassium Chloride in Out-of-hospital Cardiac Arrest Due to Refractory Ventricular Fibrillation
The purpose of this study is to evaluate, in patients presenting with out-of-hospital cardiac arrest (OHCA) by ventricular fibrillation, refractory to 3 external electric shocks, the efficacy of a direct intravenous injection of…
- Trial name
- POTACREH (NCT04316611)
- Testing
- Potassium chloride
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cardiac Arrest, Cardiopulmonary Resuscitation
Evaluation of eCPR Survivors
A cardiac arrest event has severe impact on the patient´s health-related quality of life. Survival of cardiac arrest does not innately translate to favorable quality of life.
- Conditions
- Cardiac Arrest, Cardiopulmonary Resuscitation, Extracorporeal Membrane Oxygenation Complication, Myocardial Infarction
- Trial name
- NCT05339854
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Charite University, Berlin, Germany
Septic Shock
Adjuvant Therapy With CytoSorb in Refractory Septic Shock
This prospective randomized single center study investigates to what extent the removal of elevated cytokine levels by hemoadsorption has a positive effect on the treatment of patients in septic shock by stabilizing the…
- Trial name
- ACYSS (NCT04013269)
- Testing
- CytoSorb-Therapy
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Septic Shock, Vasopressor Resistance
Evaluation of the Effect of Dexmedetomidine on Phenylephrine Response During Refractory Septic Shock
Septic shock is common in patients admitted to intensive care and hospital mortality occurs in close to 50% of these patients. In half of the cases, death occurs within the first 72 hours in a context of multiple organ failure…
- Trial name
- Adress-Pilot (NCT03953677)
- Testing
- Dexmedetomidine 100 Mcg/mL Intravenous Solution, 5% glucose Infusion solution
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Septic Shock, Cytokine Storm
Cytokine Adsorption in Severe, Refractory Septic Shock
Septic shock and the underlying dysregulated inflammatory host-response remain a major contributor to mortality in critically ill patients. Cytokine adsorption represents an attractive approach to the treatment of septic shock.
- Trial name
- NCT04910893
- Testing
- Cytokine Adsorption, Standard of Care
- Volunteers
- 48 people
- Sponsor
- University of Zurich
Neonatal Sepsis, Shock, Septic
Intravenous Methylene Blue for Treating Refractory Neonatal Septic Shock
Preterm infants (born at less than 37 weeks of pregnancy) sometimes develop a serious blood infection leading to low blood pressure, which does not respond to saline or to the standard medicines for increasing blood pressure…
- Trial name
- NCT06306001
- Testing
- Methylene Blue
- Where
- India
- Volunteers
- 130 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh